These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25869258)

  • 21. [Adherence to long-term medication: the particular case of the adjuvant endocrine therapy for breast cancer].
    Bleret V; Collignon J; Coucke P; Cusumano P; Desreux J; Herman P; Jerusalem G; Maweja S; Remacle N; Rorive A; Lifrange E
    Rev Med Liege; 2010; 65(5-6):405-8. PubMed ID: 20684428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
    Limburg C; Maxwell C; Mautner B
    Clin J Oncol Nurs; 2014 Apr; 18(2):223-30. PubMed ID: 24675258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Goserelin.
    Nurs Times; 2006 Jan 17-23; 102(3):41. PubMed ID: 16440976
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostate cancer drugs. Making sense of the options.
    Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
    [No Abstract]   [Full Text] [Related]  

  • 28. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Managing side effects of androgene deprivation in prostate cancer].
    Thalgott M; Gschwend JE; Retz M
    MMW Fortschr Med; 2010 Oct; 152(41):40-3. PubMed ID: 21090376
    [No Abstract]   [Full Text] [Related]  

  • 30. Early breast and prostate cancer and clinical outcomes (fracture).
    Chlebowski RT; Tagawa T
    Oncology (Williston Park); 2009 Dec; 23(14 Suppl 5):16-20. PubMed ID: 20128324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
    Parton M; Smith IE
    J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
    [No Abstract]   [Full Text] [Related]  

  • 33. Bilateral synchronous carcinoma of the male breast in a patient receiving estrogen therapy for carcinoma of the prostate: cause or coincidence?
    Coard K; McCartney T
    South Med J; 2004 Mar; 97(3):308-10. PubMed ID: 15043344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to adjuvant endocrine therapy in women with breast cancer.
    Danilak M; Chambers CR
    J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of skin icing for reducing pain associated with luteinizing hormone-releasing hormone agonist injection].
    Nomura T; Tsunoda K; Ohta S; Doi K; Miyoshi K; Hasegawa Y; Mizutani M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):221-4. PubMed ID: 24743201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.
    Liebertz C; Fox P
    Clin J Oncol Nurs; 2006 Jun; 10(3):361-6. PubMed ID: 16789581
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
    Güth U; Myrick ME; Schötzau A; Kilic N; Schmid SM
    Breast Cancer Res Treat; 2011 Oct; 129(3):799-807. PubMed ID: 21750963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
    BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation plus hormone therapy reduces prostate cancer mortality.
    Cancer Discov; 2014 Apr; 4(4):OF1. PubMed ID: 24706660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.